Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 89531N100 since 12/18/2024, largest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
| ELI LILLY & Co 13D | 19.9% |
10/16/2026
Event 10/13/2026
|
|
|
Pfizer Inc
13G
|
7.2% |
10/16/2026
Event 10/8/2026
|
|
| Pfizer Inc. (13-5315170) | 7.2% | ||
| Pfizer Ventures (US) LLC (82-5524518) | 4.6% | ||
|
SV Biotech Crossover Opportunities Fund LP
13D
|
7.0% |
10/16/2026
Event 10/8/2026
|
|
| SV Biotech Crossover Opportunities Fund LP | 7.0% | ||
| SV Bco I GP LLP | 7.0% | ||
|
Johnson & Johnson Innovation - JJDC, Inc.
13G
|
5.3% |
10/15/2026
Event 10/13/2026
|
|
| Johnson & Johnson Innovation - JJDC, Inc. | 5.3% | ||
| Johnson & Johnson | 5.3% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 1 | 100 | $1.52 k |